Evaluating human papillomavirus testing, prevalence, and association with prognosis in head and neck squamous cell carcinoma by subsite : A national cancer database study
Copyright © 2024 Elsevier Inc. All rights reserved..
PURPOSE: To compare human papillomavirus (HPV) testing, prevalence, and association with prognosis between head and neck squamous cell carcinoma (HNSCC) subsites.
MATERIALS AND METHODS: This study utilized the National Cancer Database (NCDB) to identify patients diagnosed with HNSCC between 2010 and 2017. Rates of HPV testing, HPV-positivity, and changes in these rates over time were measured by subsite. The impact of HPV-positivity on overall survival across six head and neck subsites was assessed using multivariable-adjusted Cox proportional hazards analysis.
RESULTS: A total of 121,550 patients were included. Of this cohort, 87,575 (72.1%) were tested for HPV, with the oropharynx (55,049/64,158; 85.8%) displaying the highest rates of testing and the sinonasal tract (1519/2853; 53.2%) displaying the lowest testing rates. Of the 86,136 with a definitive result, 46,878 (54.4%) were HPV-positive, with the oropharynx (40,313/54,205; 74.4%) displaying the highest rates of HPV-positivity and the oral cavity (1818/11,505; 15.8%) displaying the lowest. HPV-positive malignancy was associated with significantly improved adjusted overall survival in the oropharynx (HR = 0.42 [95% CI: 0.43-0.47]), oral cavity (HR = 0.86 [95% CI: 0.79-0.95]), sinonasal tract (HR = 0.63 [95% CI: 0.48-0.83]), larynx (HR = 0.78 [95% CI: 0.71-0.87]), and hypopharynx (HR = 0.56 [95% CI: 0.48-0.66]), but not the nasopharynx (HR = 0.93 [95% CI: 0.77-1.14]).
CONCLUSION: HPV testing rates were significantly lower in non-oropharyngeal subsites. This is relevant as HPV-associated disease displayed significantly improved overall survival in both the oropharynx and four of five non-oropharyngeal subsites. While validation with prospective studies is necessary, these findings may warrant HPV testing in all HNSCC subsites.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
American journal of otolaryngology - 45(2024), 3 vom: 28. Feb., Seite 104243 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barlow, Joshua [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
HPV-associated oropharyngeal squamous cell carcinoma |
|---|
| Anmerkungen: |
Date Revised 05.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.amjoto.2024.104243 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369322975 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369322975 | ||
| 003 | DE-627 | ||
| 005 | 20240306233430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amjoto.2024.104243 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM369322975 | ||
| 035 | |a (NLM)38442460 | ||
| 035 | |a (PII)S0196-0709(24)00029-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barlow, Joshua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluating human papillomavirus testing, prevalence, and association with prognosis in head and neck squamous cell carcinoma by subsite |b A national cancer database study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a PURPOSE: To compare human papillomavirus (HPV) testing, prevalence, and association with prognosis between head and neck squamous cell carcinoma (HNSCC) subsites | ||
| 520 | |a MATERIALS AND METHODS: This study utilized the National Cancer Database (NCDB) to identify patients diagnosed with HNSCC between 2010 and 2017. Rates of HPV testing, HPV-positivity, and changes in these rates over time were measured by subsite. The impact of HPV-positivity on overall survival across six head and neck subsites was assessed using multivariable-adjusted Cox proportional hazards analysis | ||
| 520 | |a RESULTS: A total of 121,550 patients were included. Of this cohort, 87,575 (72.1%) were tested for HPV, with the oropharynx (55,049/64,158; 85.8%) displaying the highest rates of testing and the sinonasal tract (1519/2853; 53.2%) displaying the lowest testing rates. Of the 86,136 with a definitive result, 46,878 (54.4%) were HPV-positive, with the oropharynx (40,313/54,205; 74.4%) displaying the highest rates of HPV-positivity and the oral cavity (1818/11,505; 15.8%) displaying the lowest. HPV-positive malignancy was associated with significantly improved adjusted overall survival in the oropharynx (HR = 0.42 [95% CI: 0.43-0.47]), oral cavity (HR = 0.86 [95% CI: 0.79-0.95]), sinonasal tract (HR = 0.63 [95% CI: 0.48-0.83]), larynx (HR = 0.78 [95% CI: 0.71-0.87]), and hypopharynx (HR = 0.56 [95% CI: 0.48-0.66]), but not the nasopharynx (HR = 0.93 [95% CI: 0.77-1.14]) | ||
| 520 | |a CONCLUSION: HPV testing rates were significantly lower in non-oropharyngeal subsites. This is relevant as HPV-associated disease displayed significantly improved overall survival in both the oropharynx and four of five non-oropharyngeal subsites. While validation with prospective studies is necessary, these findings may warrant HPV testing in all HNSCC subsites | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HPV-associated oropharyngeal squamous cell carcinoma | |
| 650 | 4 | |a Head and neck squamous cell carcinoma | |
| 650 | 4 | |a Human papillomavirus | |
| 650 | 4 | |a National Cancer Database | |
| 700 | 1 | |a Gilja, Shivee |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrandino, Rocco M |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Michael H |e verfasserin |4 aut | |
| 700 | 1 | |a Posner, Marshall R |e verfasserin |4 aut | |
| 700 | 1 | |a Bakst, Richard L |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Mohemmed N |e verfasserin |4 aut | |
| 700 | 1 | |a Teng, Marita S |e verfasserin |4 aut | |
| 700 | 1 | |a Genden, Eric M |e verfasserin |4 aut | |
| 700 | 1 | |a Chai, Raymond L |e verfasserin |4 aut | |
| 700 | 1 | |a Roof, Scott A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of otolaryngology |d 1993 |g 45(2024), 3 vom: 28. Feb., Seite 104243 |w (DE-627)NLM000961876 |x 1532-818X |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2024 |g number:3 |g day:28 |g month:02 |g pages:104243 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amjoto.2024.104243 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2024 |e 3 |b 28 |c 02 |h 104243 | ||